P/E ratio for OptiNose (OPTN)
P/E ratio as of June 2024 (TTM): -2.06
According to OptiNose's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.06. At the end of 2022 the company had a P/E ratio of -2.08.
P/E ratio history for OptiNose from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.08 | 89.9% |
| 2021 | -1.09 | -45.01% |
| 2020 | -1.99 | -43.22% |
| 2019 | -3.51 | 52.67% |
| 2018 | -2.30 | -76.61% |
| 2017 | -9.82 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.78 | 131.93% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -51.68% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.